Search Results

CSL Seqirus will supply millions of doses of adjuvanted cell-based vaccine to support Canadians, in the event the World Health Organization (WHO) declares an influenza pandemic.

https://www.cslseqirus.ca/news/canada-and-csl-seqirus-agree-on-new-pandemic-preparedness-contract

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.cslseqirus.ca/news/news-archives

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.cslseqirus.ca/news

CSL Seqirus, a business of CSL (ASX: CSL), has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to fill and finish additional pre-pandemic vaccine doses as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).

https://www.cslseqirus.ca/news/news-archives/avian

CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government’s outbreak and preparedness response.

https://www.cslseqirus.ca/news/news-archives/csl-seqirus-announces-us-government-award-in-response-to-avian-influenza

CSL Seqirus has recently opened its new high-tech cell-based influenza vaccine and antivenom manufacturing facility in Melbourne, Australia.

https://www.cslseqirus.ca/news/facility-opens-in-australia

CSL Seqirus welcomes the federal government’s announcement highlighting the creation of a new agency, Health Emergency Readiness Canada (HERC), ensuring that Canada is prepared for future health emergencies.

https://www.cslseqirus.ca/news/news-archives/health-emergency-readiness-canada

Large cluster-randomized crossover study involving nearly 430,000 U.S. adults aged 65 years and older was published in the Journal of the American Medical Association (JAMA) Network Open

https://www.cslseqirus.ca/news/published-large-us-study-finds-comparable-effectiveness-between-adjuvanted-and-high-dose

CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new actionable real-world evidence (RWE) reinforcing the critical role of enhanced influenza vaccines in preventing influenza and reducing the risks of severe disease at the 10th European Scientific Working group on Influenza (ESWI) conference in Valencia.

https://www.cslseqirus.ca/news/essential-protection-for-older-adults

Seqirus Ready to Reinforce Canada’s Influenza Pandemic Preparedness Plans

https://www.cslseqirus.ca/news/news-archives/seqirus-ready-to-reinforce-canadas--influenza-pandemic-preparedness-plans